TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18806734

Group type: EXPERIMENTAL
Intervention: 23-valent vaccine Pneumovax (0.5 mL administered intramuscularly)
Number of subjects: 51
Study: 16860190

Group type: EXPERIMENTAL
Intervention: EPO treatment (50 U/kg/wk) for 12 months
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (no treatment until hemoglobin < 9 g/dL)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 88
Study: 14585521

Group type: EXPERIMENTAL
Intervention: Estradot 50 microg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estradot 100 microg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Menorest 100 microg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Menorest 50 microg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estradot
Number of subjects: 0

Group type: COMPARATOR
Intervention: Menorest
Number of subjects: 0
Study: 11061459

Group type: EXPERIMENTAL
Intervention: Autologous bone plug
Number of subjects: 120

Group type: COMPARATOR
Intervention: Open entry point
Number of subjects: 120
Study: 9375594

Group type: EXPERIMENTAL
Intervention: Pindolol 2.5 mg p.o. t.i.d. for 2 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 10
Study: 8330544

Group type: EXPERIMENTAL
Intervention: Supplementary oxygen at 4 liters/minute through nasal cannulae
Number of subjects: 200

Group type: COMPARATOR
Intervention: No additional oxygen
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Sedation with midazolam or diazepam suspension
Number of subjects: 200
Study: 3033968

Group type: EXPERIMENTAL
Intervention: Halothane anaesthesia with DA premedication (diazepam 0.25 mg kg‐1 and atropine 0.015 mg kg‐1)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Enflurane anaesthesia
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Isoflurane anaesthesia
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: DMS premedication (diazepam 0.5 mg kg‐1, morphine 0.15 mg kg‐1, scopolamine 0.01 mg kg‐1)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Halothane anaesthesia
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Halothane, enflurane, isoflurane anaesthesia
Number of subjects: 48
Study: 29609475

Group type: EXPERIMENTAL
Intervention: Experimental Condition (EC) - smartphone-based worry-reduction training with mindfulness exercises
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control Condition (CC) - registered emotions five times daily for four weeks
Number of subjects: 136

Group type: COMPARATOR
Intervention: Waitlist Condition (WL) - not specified in detail
Number of subjects: 136
Study: 26971032

Group type: EXPERIMENTAL
Intervention: Return of voice
Number of subjects: 0
Study: 24297796

Group type: COMPARATOR
Intervention: hCG supplementation 0 IU/d (D0)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: hCG supplementation 50 IU/d (D50)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: hCG supplementation 100 IU/d (D100)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: hCG supplementation 150 IU/d (D150)
Number of subjects: 62
Study: 22762251

Group type: EXPERIMENTAL
Intervention: Astra Tech TiOblast implants
Number of subjects: 46

Group type: COMPARATOR
Intervention: Brånemark turned implants
Number of subjects: 46
Study: 21181638

Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 24
Study: 18462354

Group type: EXPERIMENTAL
Intervention: Tosufloxacin (300 mg twice daily for 2 days, initial dose 2 hours prior to biopsy)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Levofloxacin (200 mg twice daily for 2 days, initial dose 2 hours prior to biopsy)
Number of subjects: 243
Study: 17143240

Group type: EXPERIMENTAL
Intervention: MR-ICP measurement
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Normal MR-ICP value
Number of subjects: 27
Study: 12713277

Group type: EXPERIMENTAL
Intervention: 2% itraconazole cream, 5 g application
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HPbetaCD-based, emulsified wax cream formulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2% itraconazole cream
Number of subjects: 0
Study: 10934081

Group type: EXPERIMENTAL
Intervention: rPAF‐AH (1 mg/kg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 8742212

Group type: EXPERIMENTAL
Intervention: 15-minute session with a clinic nurse including an educational booklet and follow-up telephone call
Number of subjects: 293

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 293

Group type: COMPARATOR
Intervention: Educational booklet
Number of subjects: 293
Study: 1312588

Group type: EXPERIMENTAL
Intervention: Topotecan at 1.5 mg/m2
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Topotecan at 2.0 mg/m2
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Topotecan at 2.5 mg/m2
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Topotecan (all doses)
Number of subjects: 30
Study: 6397365

Group type: EXPERIMENTAL
Intervention: Highly purified semi-synthetic human insulin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Highly purified porcine insulin
Number of subjects: 24
Study: 31203685

Group type: EXPERIMENTAL
Intervention: Proparacaine HCl ophthalmic solution 0.5% plus breast milk
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Proparacaine HCl ophthalmic solution 0.5% plus sucrose 24%
Number of subjects: 51

Group type: COMPARATOR
Intervention: Proparacaine HCl ophthalmic solution 0.5%
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Sucrose group
Number of subjects: 51
Study: 29672196

Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation (twice a day for three months)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 29351139

Group type: EXPERIMENTAL
Intervention: Experimental (standard care + PPCC)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 130
Study: 27185033

Group type: EXPERIMENTAL
Intervention: Epidermal grafting (EG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Split-thickness skin grafting (SSG)
Number of subjects: 0
Study: 25388622

Group type: EXPERIMENTAL
Intervention: High-dose HAM flour cookie (33% wheat flour, 67% HAM flour)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low-dose HAM flour cookie (63% wheat flour, 37% HAM flour)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control cookie (100% wheat flour)
Number of subjects: 30
Study: 23659987

Group type: EXPERIMENTAL
Intervention: Fesoterodine therapy
Number of subjects: 498
Study: 19730258

Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 18434437

Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT): 6 weeks, 4-6 sessions per week, each session consisting of four to six 30-second 'all-out' Wingate tests with 4.5 minutes of recovery between tests
Number of subjects: 20

Group type: COMPARATOR
Intervention: Endurance Training (ET): 6 weeks, 5 sessions per week, each session consisting of 40-60 minutes of cycling at 65% of peak oxygen uptake (Vo2peak)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 20
Study: 15690267

Group type: EXPERIMENTAL
Intervention: Peribulbar block with propofol infusion
Number of subjects: 105

Group type: COMPARATOR
Intervention: Intravenous meperidine 1 mg/kg
Number of subjects: 105

Group type: COMPARATOR
Intervention: Intravenous fentanyl 2 microg/kg
Number of subjects: 105
Study: 12826215

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 2000 mg/d, CSA tapered to trough levels of 70 to 120 microg/L
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group maintained on CSA dosages and azathioprine (AZA)
Number of subjects: 14
Study: 10499601

Group type: EXPERIMENTAL
Intervention: Intradermal needle injection of rV-CEA (10^7 or 10^8 pfu)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Subcutaneous jet administration of rV-CEA (10^7 or 10^8 pfu)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both techniques (intradermal and subcutaneous)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Subcutaneous jet injection of rV-CEA
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 10^8 pfu doses of rV-CEA
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: rV-CEA vaccine
Number of subjects: 20
Study: 7700310

Group type: EXPERIMENTAL
Intervention: Kaposi's sarcoma patients (AIDS-associated, classic, and HIV-negative homosexual men)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Uninvolved skin samples from Kaposi's sarcoma patients
Number of subjects: 21
Study: 1698566

Group type: EXPERIMENTAL
Intervention: Road-to-health (RTH) chart
Number of subjects: 1221

Group type: EXPERIMENTAL
Intervention: Growth surveillance (GS) chart
Number of subjects: 1221

Group type: COMPARATOR
Intervention: No chart (control)
Number of subjects: 1221
Study: 756473

Group type: EXPERIMENTAL
Intervention: High-threat messages
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Low-threat messages
Number of subjects: 182

Group type: COMPARATOR
Intervention: Control (no communication)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: General beliefs concerning health and specific beliefs about obesity and dieting
Number of subjects: 182
Study: 31005497

Group type: EXPERIMENTAL
Intervention: Video intervention
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Handout intervention
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Video+handout intervention
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 78
Study: 28253073

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) with fixed appliance; administered monthly using a Diode laser (980 nm, 1 W, continuous wave, total energy density = 150 J/cm2)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Fixed appliance only (control group)
Number of subjects: 36
Study: 25891006

Group type: EXPERIMENTAL
Intervention: Bendamustine 60 mg/m2, thalidomide 100 mg, dexamethasone 20 mg
Number of subjects: 94

Group type: COMPARATOR
Intervention: Bendamustine 100 mg/m2
Number of subjects: 94
Study: 23263772

Group type: EXPERIMENTAL
Intervention: LY2599506 with dose titration
Number of subjects: 0

Group type: COMPARATOR
Intervention: LY2599506 with fixed dosing
Number of subjects: 0

Group type: COMPARATOR
Intervention: LY2599506 (50-400 mg BID)
Number of subjects: 0
Study: 20405185

Group type: EXPERIMENTAL
Intervention: No rubbing action
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Slight rubbing action
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vigorous rubbing action
Number of subjects: 40
Study: 19512949

Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D (25(OH)D)
Number of subjects: 242
Study: 16722591

Group type: EXPERIMENTAL
Intervention: Complete randomization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Urn randomization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adaptive randomization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stratified schemes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unstratified schemes
Number of subjects: 0
Study: 15451764

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 10930358

Group type: EXPERIMENTAL
Intervention: IV aminophylline (6 mg/kg in bolus and 1.2 mg/kg per h for maintenance)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control Group (received nebulization with fenoterol and intravenous hydrocortisone)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: IV aminophylline
Number of subjects: 43
Study: 9298177

Group type: EXPERIMENTAL
Intervention: Acarosan (acaricide) applied on mattresses and textile floor coverings
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Mattress encasings (allergen-impermeable)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo (control for acaricide)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo (control for mattress encasings)
Number of subjects: 59
Study: 7688007

Group type: EXPERIMENTAL
Intervention: Interferon (3 mU 3 times a week for 6 months)
Number of subjects: 65

Group type: COMPARATOR
Intervention: No treatment (control group for elderly)
Number of subjects: 65
Study: 3726509

Group type: EXPERIMENTAL
Intervention: Budesonide (2 X 800 micrograms daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo inhalations
Number of subjects: 12
Study: 31088335

Group type: EXPERIMENTAL
Intervention: Male patients
Number of subjects: 538

Group type: COMPARATOR
Intervention: Female patients
Number of subjects: 538

Group type: COMPARATOR
Intervention: Age-matched groups
Number of subjects: 538

Group type: COMPARATOR
Intervention: Cox regression analysis
Number of subjects: 538
Study: 29587572

Group type: EXPERIMENTAL
Intervention: Enhanced Transtheoretical Model Intervention (ETMI)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Physical Therapy
Number of subjects: 214
Study: 27178852

Group type: EXPERIMENTAL
Intervention: Scopolamine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dimenhydrinate
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cinnarizine
Number of subjects: 30
Study: 23987240

Group type: EXPERIMENTAL
Intervention: Fixed Lingual Mandibular Growth Modificator (FLMGM)
Number of subjects: 38

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 38
Study: 22154367

Group type: EXPERIMENTAL
Intervention: Low-frequency electroacupuncture (EA)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 84

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 84
Study: 20858275

Group type: EXPERIMENTAL
Intervention: HAART (Highly Active Antiretroviral Therapy)
Number of subjects: 247

Group type: COMPARATOR
Intervention: No HAART
Number of subjects: 247
Study: 18288119

Group type: EXPERIMENTAL
Intervention: Amino-acid supplementation at 3.5 g kg(‐1) per day, advanced by 1.0 g kg(‐1) per day to a maximum of 3.5 g kg(‐1) per day
Number of subjects: 122

Group type: COMPARATOR
Intervention: Amino-acid supplementation at 2.5 g kg(‐1) per day, advanced by 0.5 g kg(‐1) per day to a maximum of 2.5 g kg(‐1) per day
Number of subjects: 122
Study: 15996694

Group type: EXPERIMENTAL
Intervention: 10% paired flavor
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 90% paired flavor
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 10% paired CS
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 90% paired CS
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: US devaluation
Number of subjects: 90
Study: 12084439

Group type: EXPERIMENTAL
Intervention: Parkinson's disease (PD)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Multiple system atrophy (MSA)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Progressive supranuclear palsy (PSP)
Number of subjects: 97
Study: 10337722

Group type: EXPERIMENTAL
Intervention: Chemoprevention agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ongoing randomized phase III/IV chemoprevention trials
Number of subjects: 0
Study: 8909485

Group type: EXPERIMENTAL
Intervention: Periconceptional multivitamin use
Number of subjects: 3184
Study: 1858481

Group type: EXPERIMENTAL
Intervention: Intermittent diazepam prophylaxis (few doses per year)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acute anticonvulsant treatment with rectal diazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Long-term prophylaxis with phenobarbital or valproate
Number of subjects: 0
Study: 6628518

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 50 mg/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 100 mg/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 250 mg/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 1000 mg/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 50 mg/day for 14 days
Number of subjects: 12
Study: 30027313

Group type: EXPERIMENTAL
Intervention: FRUCT
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: FRUCTEX
Number of subjects: 12

Group type: COMPARATOR
Intervention: DEX
Number of subjects: 12
Study: 28877284

Group type: EXPERIMENTAL
Intervention: Icon infiltrant (DMG)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Alpha Seal‐DFL (commercial pit‐and‐fissure sealant)
Number of subjects: 23
Study: 25251104

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (PIPC/TAZ) 337.5 mg/kg/day
Number of subjects: 53

Group type: COMPARATOR
Intervention: Cefepime (CFPM) 100 mg/kg/day
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (PIPC/TAZ)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Cefepime (CFPM)
Number of subjects: 53
Study: 23812801

Group type: EXPERIMENTAL
Intervention: Intravaginal application of 500 μL of Fresh seminal plasma
Number of subjects: 230

Group type: COMPARATOR
Intervention: Culture medium (placebo)
Number of subjects: 230
Study: 21272844

Group type: EXPERIMENTAL
Intervention: Day-case laparoscopic supracervical hysterectomy
Number of subjects: 49

Group type: COMPARATOR
Intervention: Overnight hospital stay after laparoscopic supracervical hysterectomy
Number of subjects: 49
Study: 19851122

Group type: EXPERIMENTAL
Intervention: Tailored, four-visit, in-home symptom-focused diabetes intervention
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Tailored, four-visit, in-home symptom-focused diabetes intervention with booster telephone calls
Number of subjects: 180

Group type: COMPARATOR
Intervention: Attentional control focused on skills training for weight management and diet
Number of subjects: 180
Study: 15818287

Group type: EXPERIMENTAL
Intervention: Gatifloxacin (10 mg/kg of body weight once daily for 10 days)
Number of subjects: 413

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (45/6.4 mg/kg/d in 2 divided doses for 10 days)
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Gatifloxacin
Number of subjects: 413

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate
Number of subjects: 413
Study: 14570093

Group type: EXPERIMENTAL
Intervention: Supportive care and whole-brain radiotherapy (WBRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supportive care alone
Number of subjects: 0
Study: 10472216

Group type: EXPERIMENTAL
Intervention: Pulse contour analysis (PCCO)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Continuous thermodilution technique (CCO)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Intermittent bolus thermodilution technique (BCO)
Number of subjects: 26
Study: 10163467

Group type: EXPERIMENTAL
Intervention: Immediate vitrectomy
Number of subjects: 420

Group type: COMPARATOR
Intervention: Tap and biopsy with no systemic antibiotics
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Systemic antibiotics (ceftazidime and amikacin)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Patients with light-perception-only visual acuity
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Patients with hand motion acuity or better
Number of subjects: 420
Study: 1908138

Group type: EXPERIMENTAL
Intervention: Negative pressure ventilation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard treatment (control)
Number of subjects: 20
Study: 6619027

Group type: EXPERIMENTAL
Intervention: Azlocillin
Number of subjects: 44

Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 44
Study: 30430338

Group type: EXPERIMENTAL
Intervention: 10% hydrogen peroxide whitening strips (Crest® 3D Whitestrips® premium plus)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group (non‐whitening strip exposed)
Number of subjects: 113
Study: 28922091

Group type: EXPERIMENTAL
Intervention: Information
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Information and Support
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Information, Support, and Coaching (Full CHESS)
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Full CHESS and Mentor
Number of subjects: 443
Study: 26160149

Group type: EXPERIMENTAL
Intervention: Self-managed exercise programme
Number of subjects: 86

Group type: COMPARATOR
Intervention: Usual physiotherapy treatment
Number of subjects: 86
Study: 23551623

Group type: EXPERIMENTAL
Intervention: ANKYLOS plus® implants (A-implants)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Certain® PREVAIL(TM) (B-implants)
Number of subjects: 18
Study: 23739317

Group type: EXPERIMENTAL
Intervention: Autologous platelet rich fibrin
Number of subjects: 15

Group type: COMPARATOR
Intervention: Open flap debridement alone
Number of subjects: 15
Study: 19708635

Group type: EXPERIMENTAL
Intervention: C4‐5 facet joint injection
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (unilateral multifidi muscle injection)
Number of subjects: 89
Study: 18303675

Group type: EXPERIMENTAL
Intervention: Phacoemulsification and foldable IOL implantation
Number of subjects: 118

Group type: COMPARATOR
Intervention: Modified tunnel incision non-phacoemulsification and foldable IOL implantation
Number of subjects: 118
Study: 15888064

Group type: EXPERIMENTAL
Intervention: cyclosporine‐mycophenolate mofetil (n = 85)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: high‐level tacrolimus (TAC) (8‐12 ng/mL)‐low‐level sirolimus (SRL) (3‐7 ng/mL) (n = 72)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: low‐level TAC (3‐7 ng/mL)‐high‐level SRL (8‐12 ng/mL) (n = 82)
Number of subjects: 239

Group type: COMPARATOR
Intervention: SRL-treated recipients
Number of subjects: 239
Study: 11923699

Group type: EXPERIMENTAL
Intervention: C2 (2-hr post-dose cyclosporine monitoring)
Number of subjects: 307

Group type: COMPARATOR
Intervention: C0 (conventional trough cyclosporine monitoring)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: C2
Number of subjects: 307

Group type: COMPARATOR
Intervention: C0
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: C2 (patients reaching minimum target CsA levels by day 3)
Number of subjects: 307
Study: 9509801

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0